1887
Letter Open Access
Like 0
Preview this article:
Zoom in
Zoomout

Letter to the editor: Importance of serum bactericidal activity for estimating the breadth of protection for new meningococcal vaccines, Page 1 of 1

| /docserver/preview/fulltext/eurosurveillance/21/15/eurosurv-21-30191-8-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.15.30191
2016-04-14
2017-11-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2016.21.15.30191
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/15/eurosurv-21-30191-8.html?itemId=/content/10.2807/1560-7917.ES.2016.21.15.30191&mimeType=html&fmt=ahah

References

  1. Brehony C, Hill DM, Lucidarme J, Borrow R, Maiden MC. Meningococcal vaccine antigen diversity in global databases. Euro Surveill. 2015;20(49):30084.  https://doi.org/10.2807/1560-7917.ES.2015.20.49.30084  PMID: 26676305 
  2. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, et al. Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24(24):5093-107.  https://doi.org/10.1016/j.vaccine.2006.03.091  PMID: 16838413 
  3. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(Suppl 2):B112-6.  https://doi.org/10.1016/j.vaccine.2009.04.065  PMID: 19464093 
  4. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511-20.  https://doi.org/10.1056/NEJMra0906357  PMID: 20410516 
  5. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O’Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3-12.  https://doi.org/10.1016/j.vaccine.2009.04.071  PMID: 19481313 
  6. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088-100.  https://doi.org/10.1128/IAI.72.4.2088-2100.2004  PMID: 15039331 
  7. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086-93.  https://doi.org/10.1016/j.vaccine.2010.06.083  PMID: 20619376 
  8. Harris SL, Zhu D, Murphy E, McNeil LK, Wang X, Mayer LW, et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease. Hum Vaccin. 2011;7(sup1) Suppl;68-74.  https://doi.org/10.4161/hv.7.0.14564  PMID: 21245657 
  9. Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J. 2012;31(10):1061-8. PMID: 22718089 
  10. Marshall HS, Richmond PC, Nissen MD, Wouters A, Baber J, Jiang Q, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;31(12):1569-75.  https://doi.org/10.1016/j.vaccine.2013.01.021  PMID: 23352429 
  11. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2013;32(4):364-71.  https://doi.org/10.1097/INF.0b013e31827b0d24  PMID: 23114369 
  12. Reiner DM, Bhuyan P, Eiden JJ, Ginis J, Harris S, Jansen KU, et al. Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. Vaccine. 2016;34(6):809-13.  https://doi.org/10.1016/j.vaccine.2015.12.016  PMID: 26707218 
  13. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, et al. 2001 Study Investigators. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(8):597-607.  https://doi.org/10.1016/S1473-3099(12)70087-7  PMID: 22569484 
  14. Vesikari T, Østergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, et al. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. J Pediatric Infect Dis Soc. 2015;piv039.  https://doi.org/10.1093/jpids/piv039  PMID: 26407272 
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error